AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03152123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Pitolisant 40 mg or 240 mg (tablets over-capsuled)
Study NCT03152123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: tablets over-capsuled
Study NCT03152123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Phentermine 60 mg (capsule over-capsuled)
Study NCT03362268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
Study NCT03362268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
Study NCT04306718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: membrane peeling
Description: ERM and ILM are peeled routinely during surgery
Study NCT00668863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Description: FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00668863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study NCT02995655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-01
Description: CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
Study NCT02995655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
Study NCT02995655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Description: -Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
Study NCT04098705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Introduction of the World Health Organization Triage Scale
Description: The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol.
Study NCT02995655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
Study NCT01933464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01316263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT04325776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
Study NCT04325776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Injection
Description: Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
Study NCT03544268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes.
Study NCT03544268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study NCT04240691 — intervention group
Intervention type: BEHAVIORAL
Intervention: 60-Minutes-For-Health
Description: Refer to description under Groups
Study NCT04240691 — intervention group
Intervention type: OTHER
Intervention: Time-and-Attention Control Session
Description: Refer to description under Groups
Study NCT02834234 — intervention group
Intervention type: GENETIC
Intervention: comparative genomic analysis
Description: DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
Study NCT02483429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRT Care
Description: The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
Study NCT04427917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: PF-06835919 300 mg repeated doses
Study NCT04427917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo repeated doses
Study NCT02863367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib：500 mg，po，qd, d1-14, every 3 week
Study NCT02863367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
Study NCT01144234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Invitation letter for male spouse
Description: In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
Study NCT01144234 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information letter
Description: In this arm the pregnant women got an information letter
Study NCT02632500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of chest compressions
Study NCT00261170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: 150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
Study NCT00261170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
Study NCT01802554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant Events Program (PEP)
Description: Behavioral Activation Therapy
Study NCT01802554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support (IS)
Description: Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
Study NCT02723292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOP
Study NCT02723292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Study NCT02204826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
Study NCT02204826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
Study NCT02204826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
Study NCT02204826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
Study NCT02204826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
Study NCT01895452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Low Dose
Description: Intramuscular injection, given monthly
Study NCT01895452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, High Dose
Description: Intramuscular injection, given monthly
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT04221893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo radiation therapy
Study NCT01604460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation with torso plastic bag
Description: Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
Study NCT01604460 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Resuscitation-no plastic bag
Description: Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
Study NCT00951392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: euglycemic hyperinsulinemic clamp
Description: Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests
Study NCT00951392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip
Study NCT00951392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: energy expenditure measurement
Study NCT02382354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
Study NCT02382354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
Study NCT02382354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: I-gel insertion was inserted 5 min after anesthesia induction
Study NCT02382354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask airway
Description: laryngeal mask airway insertion was inserted 5 min after anesthesia induction
Study NCT02382354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
Study NCT02382354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
Study NCT03722979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac surgery
Description: The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT02260648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00902330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: energy-based therapy
Description: Given once a day for 18 weeks
Study NCT00902330 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Given once a day for 18 weeks
Study NCT03560492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: 5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
Study NCT03560492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture garment
Description: Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
Study NCT04278248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: 1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
Study NCT04278248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: 1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
Study NCT01485848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP-100
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study NCT01485848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study NCT04025892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily weighing
Description: Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
Study NCT03467516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
Study NCT01059747 — intervention group
Intervention type: OTHER
Intervention: no intervention applied
Description: no intervention applied
Study NCT00691392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
Study NCT00691392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Methylcellulose - Placebo
Description: The placebo will be over-encapsulated microcrystalline methylcellulose
Study NCT03446430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PWV measurement by LDV
Description: PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
Study NCT01529229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine + Betamethasone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study NCT01529229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine + Prednisolone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study NCT01977378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained-Release Desvenlafaxine Hydrochloride
Study NCT01977378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-Release Venlafaxine Hydrochloride
Study NCT03709524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq + fiberoptic
Description: video laryngoscope with a monitor
Study NCT03534388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Hypochlorite Cleanser
Description: Cleansing with CLn BodyWash
Study NCT01900886 — intervention group
Intervention type: OTHER
Intervention: Peginterferon alfa-2a
Description: Treatment as usual clinical practice
Study NCT01900886 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Treatment as usual clinical practice
Study NCT04596722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomella
Description: Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts
Study NCT04596722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts